Sihuan Kebao Pharmaceutical

Beijing Kebao Pharmaceutical is a prominent Chinese pharmaceutical company and a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group. Established as a core manufacturing and R&D hub, the company focuses on high-value therapeutic areas including cardiovascular, cerebrovascular, and metabolic diseases. Its product portfolio is headlined by Alprostadil Liposomal Injection, a leading treatment for peripheral vascular conditions in the Chinese market. The company operates advanced GMP-certified facilities in Beijing, supporting the production of both chemical drugs and complex formulations. As part of the larger Sihuan Group, Beijing Kebao plays a critical role in the group's strategy to transition from a generics-focused business to an innovation-driven biopharmaceutical leader.